Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation

American Journal of Hematology

Volumn 87, Issue 12, 2012, Pages 1074-1078

  El Cheikh, Jean ^a   Vazquez, Alberto ^a   Crocchiolo, Roberto ^a   Furst, Sabine ^a   Calmels, Boris ^a   Castagna, Luca ^a   Lemarie, Claude ^a   Granata, Angela ^a   Ladaique, Patrick ^a   Oudin, Claire ^a   Faucher, Catherine ^a   Chabannon, Christian ^a   Blaise, Didier ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; FLUDARABINE; FLUDARABINE PHOSPHATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD3+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; UNRELATED DONORS;

ADULT; AGED; ANTIGENS, CD3; CHIMERISM; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84869198304     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23319     Document Type: Article

References (30)

1. Bacigalupo A, Ballen K, Rizzo D, Giralt S, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
3. Gratwohl A, Stern M, Brand R, Apperley J, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715-4726.
4. Bai L, Deng YM, Dodds AJ, Milliken S, et al. A SYBR green-based real-time PCR method for detection of haemopoietic chimerism in allogeneic haemopoietic stem cell transplant recipients. Eur J Haematol 2006; 77: 425-431.
5. Wiedemann B, Klyuchnikov E, Kroger N, Zabelina T, et al. Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. Exp Hematol 2010; 38: 1261-1271.
6. Bader P, Niethammer D, Willasch A, Kreyenberg H, et al. How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35: 107-119.
7. Childs R, Clave E, Contentin N, Jayasekera D, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
8. Antin JH, Childs R, Filipovich AH, Giralt S, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001; 7: 473-485.
9. Khan F, Agarwal A, Agrawal S. Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant 2004; 34: 1-12.
10. Baron F, Baker JE, Storb R, Gooley TA, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104: 2254-2262.
11. Miura Y, Tanaka J, Toubai T, Tsutsumi Y, et al. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation. Bone Marrow Transplant 2006; 37: 837-843.
12. Mohty M, Avinens O, Faucher C, Viens P, et al. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007; 92: 1004-1006.
13. Seong CM, Giralt S, Kantarjian H, Xu J, et al. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol 2000; 18: 1831-1836.
14. Chalandon Y, Vischer S, Helg C, Chapuis B, et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Geneva experience. Leukemia 2003; 17: 228-231.
15. Alizadeh M, Bernard M, Danic B, Dauriac C, et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618-4625.
16. Fehse B, Chukhlovin A, Kuhlcke K, Marinetz O, et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001; 10: 419-425.
17. Koldehoff M, Steckel NK, Hlinka M, Beelen DW, et al. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences. Am J Hematol 2006; 81: 735-746.
18. Thiede C. Diagnostic chimerism analysis after allogeneic stem cell transplantation: new methods and markers. Am J Pharmacogenomics 2004; 4: 177-187.
19. Gardiner N, Lawler M, O'Riordan J, De'Arce M, et al. Donor chimerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia. Leukemia 1997; 11 Suppl 3: 512-515.
20. Lawler M, McCann SR, Marsh JC, Ljungman P, et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol 2009; 144: 933-945.
21. Giralt S, Ballen K, Rizzo D, Bacigalupo A, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369.
22. Martinelli G, Trabetti E, Zaccaria A, Farabegoli P, et al. In vitro amplification of hypervariable DNA regions for the evaluation of chimerism after allogeneic BMT. Bone Marrow Transplant 1993; 12: 115-120.
23. Barrios M, Jimenez-Velasco A, Roman-Gomez J, Madrigal ME, et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003; 88: 801-810.
24. van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, et al. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse. Blood 1994; 83: 3059-3067.
25. Huisman C, de Weger RA, de Vries L, Tilanus MG, et al. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007; 39: 285-291.
26. Mohty M, Jacot W, Faucher C, Bay JO, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177.
27. Lamba R, Abella E, Kukuruga D, Klein J, et al. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia 2004; 18: 1681-1686.
28. Keil F, Prinz E, Moser K, Mannhalter C, et al. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation 2003; 76: 230-236.
29. Lange T, Hubmann M, Burkhardt R, Franke GN, et al. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 2011; 25: 498-505.
30. Mickelson DM, Sproat L, Dean R, Sobecks R, et al. Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46: 84-89.